Global Statistics Representing Subdermal Contraceptive Implants Market Scenario
Subdermal contraceptive implants are small matchstick-sized plastic rods, which are inserted under the skin on the inside of the upper arm, with the help of local anesthesia. Once implanted, it releases a hormone etonogestrel (a progestin) at an average rate of 50 mcg/day for a duration of 3–5 years. The release of progestin from the implant efficiently provides contraception and birth control even in the situation of unprotected sex. Additionally, the medical and healthcare practitioners complete 3 hours of manufacturer-sponsored training before removing or inserting the contraceptive implant. Nowadays, subdermal contraceptives are inserted with the help of an insertion applicator, where there is no need for incision and helps to avoid deep insertion of an implant. For the record, subdermal contraceptive implants are radiopaque, which makes it easy to locate at the time of removal.
A subdermal contraceptive implant can be inserted in the female body any time during the menstrual cycle. Generally, it is inserted in the first 5 days of the menstrual cycle. The side effects caused by subdermal contraceptive include amenorrhea, headache, and irregular vaginal bleeding. An incision is required to be made on the body in order to remove the implant, after which immediate normalization of ovarian activity occurs. As per the United Nations-Department of Economic and Social Affairs, about 842 million women use modern methods of contraception across the globe. However, implants are being used by only 2% of the women, which is further hampering the market growth to some extent.
Globally, the rising adoption of modern and safe contraceptive methods, growing expenditure power, and increasing government support for population control is driving the global subdermal contraceptive implants market. Population control is a global concern to be taken care of, which is expected to boost the subdermal contraceptive implants market growth. Other factors driving the market include the rising concern regarding sexual health, unintended pregnancies, and surge in the number of abortions. For the record, the subdermal contraceptive implants are 99% effective, offer quick regain of the natural fertility after the removal of the implant compared to other options, and are beneficial for women allergic to estrogen. In general, the use of other contraceptive causes irregular menstrual cycles, occasional vaginal bleeding, severe mood swing disorder, fatigue, and headache.
Some of the factors hampering the market include the psychological side effects of the contraceptive implants, chances of failure, availability of substitutes, and a well-flourished market of contraceptive pills and condoms. The subdermal contraceptive cannot be implanted in the body during pregnancy and can cause undiagnosed vaginal bleeding, blood clots in legs, migraine, breast cancer, and severe liver disease, which is further restricting the market growth to some extent.
Global subdermal contraceptive implants market was valued at USD 763.4 million in 2018 and is expected to grow at a CAGR of 12.6% during the forecast period.
The global subdermal contraceptive implants market is segmented into type, end-users, and region.
By type, the global subdermal contraceptive implants market is segmented into non-biodegradable and biodegradable. The non-biodegradable segment is expected to account for the largest share in the subdermal contraceptive implants market as it is cost-effective and offers about 99% efficacy in birth control. It is implanted in the body by a certified and trained medical practitioner. Similarly, it is removed by a medical practitioner after completing 3 hours of manufacturer-sponsored training and leaves no traces of birth control practices, which is further driving the segment growth.
The biodegradable segment is emerging in the subdermal contraceptive implants market. Currently, the biodegradable subdermal contraceptive implants are in the clinical trial phase and are expected to be marketed by 2026. For instance, Capronor, a 4.0 cm biodegradable subdermal contraceptive implant, is being tested in the clinical trial phase II. During 12 months of testing on 41 women, the implant showed no serious side effects and is being called as a safe and long-effective contraceptive implant, which is further adding fuel to the market growth.
Based on end-users, the subdermal contraceptive implants market is segmented into hospitals, gynecology clinics, and women healthcare centers. The gynecology clinics segment is expected to grab one of the highest shares in the market on account of increasing patient visits for the implantation and removal of subdermal contraceptives.
The hospital's segment is expected to account for optimum share among end-users. The availability of advanced diagnostics systems and treatment options across major hospitals is likely to boost the segment growth during the forecast period. The governments across the globe are partnering with hospitals to provide male and female contraceptives at lower prices. In countries with a high population, such as India and China, the governments are providing free of cost contraception to control the growing population and rising prevalence of sexually transmitted diseases.
Regionally, the global subdermal contraceptive implants market is segmented into the Americas, Europe, Asia Pacific, and the Middle East & Africa.
Americas is dominating the global subdermal contraceptive implants market and will continue the same during the forecast period. In the region, Central America is accounting for the largest share due to the increasing demand for contraceptive implants, rapidly advancing healthcare infrastructure and rising medical tourism. Similarly, North America's subdermal contraceptive implants market is growing at a significant pace. This can be attributed to the well-developed healthcare infrastructure, rising prevalence of sexually transmitted diseases, and increasing healthcare expenditure. Subdermal contraceptive implants are witnessing huge demand in the region due to its high efficacy, long period of contraception, and easy insertion and removal of the implant. Other factors driving the market include the ongoing advancements in contraceptive implants and the rising number of working women across the region.
Europe is second in the subdermal contraceptive implants market. The region is backed with the presence of leading subdermal contraceptive implants manufacturers that are constantly working to provide innovative products and are performing extensive R&D activities for the same. As per the United Nations-Department of Economic and Social Affairs, the Northern European countries, including Estonia, Finland, Denmark, Latvia, Ireland, Sweden, Norway, United Kingdom of Great Britain, and Northern Ireland are the major contributors to the subdermal contraceptive implant market, which is further boosting the market growth.
Some of the key players in the global subdermal contraceptive implants market include Bayer AG, Merck & Co. Inc., and Shanghai Dahua Pharmaceutical Co., Ltd. The market for subdermal contraceptive implants is highly fragmented in nature, with different market players operating in local regions. Some of the key players are engaging in acquisitions, collaborations, and partnerships to gain a competitive edge. For instance,
Product Offerings by Key Players
Product- Jadelle (Disposable, Sterile Trocar)
Registration- Registered (in 1X10 standard package) in 41 countries. However, the registrations are pending in about eight additional countries. It has also registered in a single-pack presentation for sales through the private sector.
Merck & Co. Inc.
Product- Implanon and Implanon NXT (Preloaded, Disposable, Sterile Insertion Device)
Registration- Implanon is registered in 60 countries. Review underway in 11 additional countries
Implanon NXT is registered in 38 countries. Pending registrations in 11 additional countries
Shanghai Dahua Pharmaceutical Co., Ltd.
Product- Sino-implant (II) (Disposable, Sterile Trocar)
Registration- Registered in 24 countries. Pending registration in 11 additional countries
WHO Prequalification- Not prequalified, World Health Organization good manufacturing process (GMP) certified, the prequalification application under review
Subdermal Contraceptive Implants Market Segmentation
By End Users
Frequently Asked Questions (FAQs)